| Literature DB >> 27212611 |
S Vieillefosse1, J Guibourdenche2, A Atallah3, B Haddad4, T Fournier5, V Tsatsaris6, E Lecarpentier7.
Abstract
Preeclampsia is characterized by the association of hypertension and a de novo proteinuria in the second half of pregnancy. Currently, obstetrical teams do not have any tool to detect during the first trimester of pregnancy, in low risk population, the patients likely to develop early and severe preeclampsia. On the other hand, there is no diagnostic/prognostic tool in case of strong suspicion of preeclampsia. The Placental Growth Factor (PIGF) and soluble receptor of the Vascular Endothelial Growth Factor (sFlt-1) are respectively two molecules pro- and anti-angiogenic released mainly by the placenta during pregnancy. Numerous experimental and clinical results suggest that an imbalance of pro/anti-angiogenic factors is involved in the pathophysiology of preeclampsia. We selected and analyzed the main studies that have evaluated the predictive, diagnostic and prognostic value of these two biomarkers for preeclampsia.Entities:
Keywords: Angiogenic factors; Biomarkers; Biomarqueurs; Facteurs angiogéniques; Grossesse; PlGF; Placental growth factor; Prediction; Preeclampsia; Prognosis; Prédiction; Prééclampsie; SFlt-1; sFLT-1
Mesh:
Substances:
Year: 2016 PMID: 27212611 DOI: 10.1016/j.jgyn.2016.02.006
Source DB: PubMed Journal: J Gynecol Obstet Biol Reprod (Paris) ISSN: 0150-9918